 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- levodopa/carbidopa (ND0680) / Mitsubishi Tanabe
QUALITY OF LIFE WITH 24-HOUR SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION (ND0612): QOL RESULTS FROM A PHASE 3 RANDOMIZED, ACTIVE-CONTROLLED STUDY () - Mar 10, 2025 - Abstract #ADPD2025ADPD_1202;
P3
ND0612 improved QoL compared to IR-LD/CD, further supporting the clinical meaningfulness of the observed reduction in motor fluctuations from the perspective of a patient with PD.
- levodopa/carbidopa (ND0680) / Mitsubishi Tanabe
ONE YEAR EFFICACY AND SAFETY OF ND0612 FOR MOTOR FLUCTUATIONS IN PARKINSON () - Mar 10, 2025 - Abstract #ADPD2025ADPD_1057;
ND0612 improved QoL compared to IR-LD/CD, further supporting the clinical meaningfulness of the observed reduction in motor fluctuations from the perspective of a patient with PD. Aims: The double-blind phase of the BouNDless study demonstrated that treatment with investigational ND0612 provided patients with Parkinson
- | levodopa/carbidopa (ND0680) / Mitsubishi Tanabe
Journal: Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study. (Pubmed Central) - Feb 22, 2025
P2
Three-year results from this open-label study support the long-term safety, tolerability, and efficacy of ND0612. For participants who entered the extension phase, the high rate of retention supports a favorable benefit-risk ratio of the ND0612 regimen for patients with PD experiencing motor fluctuations.